Compare SDSTW & CYCN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDSTW | CYCN |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | United States |
| Employees | 10 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 6.8M | 5.7M |
| IPO Year | N/A | N/A |
| Metric | SDSTW | CYCN |
|---|---|---|
| Price | $0.15 | $3.22 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.9K | ★ 26.3K |
| Earning Date | 03-26-2025 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.02 | $1.03 |
| 52 Week High | $0.30 | $8.48 |
| Indicator | SDSTW | CYCN |
|---|---|---|
| Relative Strength Index (RSI) | 54.33 | 58.11 |
| Support Level | $0.10 | $2.88 |
| Resistance Level | $0.16 | $3.42 |
| Average True Range (ATR) | 0.01 | 0.15 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 71.53 | 65.91 |
Stardust Power Inc is developing a lithium refinery at its Facility in Muskogee, Oklahoma, with planned capacity of producing up to 50,000 metric tons per annum of BGLC once fully operational. The company will source lithium brine feedstock from various suppliers and may make investments upstream to secure additional feedstock. The Company seeks to sell its products to electric vehicle (EV) manufacturers as the primary market, with potential applications in other areas such as battery manufacturers, the U.S. military, and original equipment manufacturers (OEMs).
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.